PARIS--(BUSINESS WIRE)--Regulatory News:
STENTYS (Paris:STNT) (FR0010949404 – STNT), a French group specialized in medical technologies for interventional cardiology, today reported its consolidated quarterly revenues and cash position at March 31, 2020.
First-quarter revenues by geographical region
€ thousands |
Q1 2020 |
Q1 2019 |
% change |
Europe1 |
442 |
1,357 |
-67% |
Rest of the world |
315 |
1,243 |
-75% |
Total revenues |
757 |
2,600 |
-71% |
Audited data |
First-quarter revenues by product category
€ thousands |
Q1 2020 |
Q1 2019 |
% change |
Stents |
133 |
1,638 |
-92% |
Balloons & accessories |
624 |
961 |
-35% |
Total revenues |
757 |
2,600 |
-71% |
Audited data |
During the first quarter of 2020, the Company liquidated its inventories. On the date of publication of this press release, the Company no longer has regulatory clearance to market its products. Unsold products have been destroyed. STENTYS will henceforth generate no further revenues.
Cash position of €6.1 million
The Group had a cash position of €6.1 million at March 31, 2020 versus €8.2 million at December 31, 2019.
Additional information is available at www.stentys.com.
STENTYS is listed on Compartment C of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT
***
Forward-looking statements
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2016 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on November 29, 2017 under number D.17-1084.
-------------------------------
1Gerrmany, Italy, Switzerland, Austria, Poland, Netherlands, France, Belgium, United Kingdom, Spain, Greece, Portugal and Nordic countries.
